Get started
Sangamo Therapeutics, Inc.Sangamo Therapeutics, Inc.Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

GBY chart


Full chart

GBY upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪140.39 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.24 EUR
Net income (FY)
‪−94.61 M‬ EUR
Revenue (FY)
‪55.83 M‬ EUR
Shares float
‪291.68 M‬
Beta (1Y)
1.61

Employees


Employees (FY)
183
Change (1Y)
−222 −54.81%
Revenue / Employee (1Y)
‪305.10 K‬ EUR
Net income / Employee (1Y)
‪−516.99 K‬ EUR

About Sangamo Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Alexander D. Macrae
Website
sangamo.com
Headquarters
Richmond
Founded
1995
ISIN
US8006771062
FIGI
BBG00FZMG7X0
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Check out other big names from the same industry as GBY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

GBY news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of GBY is 0.45 EUR — it has decreased by −3.02% in the past 24 hours. Watch Sangamo Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange Sangamo Therapeutics, Inc. stocks are traded under the ticker GBY.
GBY stock has risen by 4.18% compared to the previous week, the month change is a 13.86% rise, over the last year Sangamo Therapeutics, Inc. has showed a −31.07% decrease.
We've gathered analysts' opinions on Sangamo Therapeutics, Inc. future price: according to them, GBY price has a max estimate of 8.52 EUR and a min estimate of 1.28 EUR. Watch GBY chart and read a more detailed Sangamo Therapeutics, Inc. stock forecast: see what analysts think of Sangamo Therapeutics, Inc. and suggest that you do with its stocks.
GBY reached its all-time high on Mar 7, 2018 with the price of 99.65 EUR, and its all-time low was 0.27 EUR and was reached on Nov 13, 2023. View more price dynamics on GBY chart.
See other stocks reaching their highest and lowest prices.
GBY stock is 5.54% volatile and has beta coefficient of 1.61. Track Sangamo Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Sangamo Therapeutics, Inc. there?
Today Sangamo Therapeutics, Inc. has the market capitalization of ‪140.39 M‬, it has decreased by −4.24% over the last week.
Yes, you can track Sangamo Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Sangamo Therapeutics, Inc. is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
GBY earnings for the last quarter are −0.07 EUR per share, whereas the estimation was −0.01 EUR resulting in a −694.68% surprise. The estimated earnings for the next quarter are 0.00 EUR per share. See more details about Sangamo Therapeutics, Inc. earnings.
Sangamo Therapeutics, Inc. revenue for the last quarter amounts to ‪15.54 M‬ EUR, despite the estimated figure of ‪26.89 M‬ EUR. In the next quarter, revenue is expected to reach ‪29.25 M‬ EUR.
GBY net income for the last quarter is ‪−16.97 M‬ EUR, while the quarter before that showed ‪−28.28 M‬ EUR of net income which accounts for 40.01% change. Track more Sangamo Therapeutics, Inc. financial stats to get the full picture.
No, GBY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 9, 2025, the company has 183 employees. See our rating of the largest employees — is Sangamo Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sangamo Therapeutics, Inc. EBITDA is ‪−48.96 M‬ EUR, and current EBITDA margin is −155.31%. See more stats in Sangamo Therapeutics, Inc. financial statements.
Like other stocks, GBY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sangamo Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Sangamo Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Sangamo Therapeutics, Inc. stock shows the sell signal. See more of Sangamo Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.